Princeton Global Asset Management LLC Sells 4,093 Shares of Merck & Co., Inc. (NYSE:MRK)

Princeton Global Asset Management LLC decreased its position in Merck & Co., Inc. (NYSE:MRK) by 30.3% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,394 shares of the company’s stock after selling 4,093 shares during the period. Princeton Global Asset Management LLC’s holdings in Merck & Co., Inc. were worth $843,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the company. Napatree Capital LLC lifted its position in shares of Merck & Co., Inc. by 13.0% during the 4th quarter. Napatree Capital LLC now owns 4,220 shares of the company’s stock worth $420,000 after buying an additional 485 shares during the period. Littlejohn Financial Services Inc. acquired a new position in Merck & Co., Inc. during the 4th quarter valued at about $2,080,000. Raab & Moskowitz Asset Management LLC boosted its stake in Merck & Co., Inc. by 17.7% in the fourth quarter. Raab & Moskowitz Asset Management LLC now owns 56,307 shares of the company’s stock valued at $5,601,000 after acquiring an additional 8,461 shares during the last quarter. Global Wealth Management Investment Advisory Inc. boosted its position in shares of Merck & Co., Inc. by 102.2% in the 4th quarter. Global Wealth Management Investment Advisory Inc. now owns 45,057 shares of the company’s stock worth $4,482,000 after purchasing an additional 22,775 shares during the last quarter. Finally, Sumitomo Mitsui DS Asset Management Company Ltd boosted its holdings in Merck & Co., Inc. by 1.7% during the fourth quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 632,355 shares of the company’s stock worth $62,907,000 after buying an additional 10,332 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Merck & Co., Inc.

In related news, SVP Dalton E. Smart III sold 4,262 shares of the firm’s stock in a transaction on Friday, April 25th. The stock was sold at an average price of $82.76, for a total transaction of $352,723.12. Following the sale, the senior vice president now owns 7,778 shares of the company’s stock, valued at $643,707.28. This trade represents a 35.40% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 0.13% of the company’s stock.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $78.95 on Friday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $134.63. The company’s 50 day moving average price is $79.13 and its two-hundred day moving average price is $89.96. The firm has a market cap of $198.25 billion, a PE ratio of 11.73, a PEG ratio of 0.77 and a beta of 0.43. The company has a quick ratio of 1.15, a current ratio of 1.36 and a debt-to-equity ratio of 0.79.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 24th. The company reported $2.22 EPS for the quarter, beating analysts’ consensus estimates of $2.16 by $0.06. Merck & Co., Inc. had a return on equity of 45.35% and a net margin of 26.67%. The business had revenue of $15.53 billion during the quarter, compared to the consensus estimate of $15.59 billion. During the same quarter in the previous year, the firm earned $2.07 earnings per share. Merck & Co., Inc.’s revenue for the quarter was down 1.6% compared to the same quarter last year. Equities research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, July 8th. Stockholders of record on Monday, June 16th will be issued a dividend of $0.81 per share. The ex-dividend date is Monday, June 16th. This represents a $3.24 dividend on an annualized basis and a dividend yield of 4.10%. Merck & Co., Inc.’s dividend payout ratio (DPR) is currently 47.16%.

Analyst Upgrades and Downgrades

MRK has been the subject of several research analyst reports. Cantor Fitzgerald lowered shares of Merck & Co., Inc. from an “overweight” rating to a “cautious” rating in a report on Tuesday, May 20th. TD Securities cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and decreased their price target for the stock from $121.00 to $100.00 in a research note on Monday, February 10th. Wall Street Zen cut Merck & Co., Inc. from a “strong-buy” rating to a “buy” rating in a report on Friday, April 25th. Guggenheim restated a “buy” rating and set a $115.00 target price on shares of Merck & Co., Inc. in a report on Thursday, April 17th. Finally, Deutsche Bank Aktiengesellschaft downgraded Merck & Co., Inc. from a “buy” rating to a “hold” rating and lowered their price target for the stock from $128.00 to $105.00 in a research report on Tuesday, February 18th. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating, seven have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $109.19.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.